AOD-9604 dosing — commonly cited daily range

There is no established AOD-9604 dosage, because no human trial ever demonstrated an effective dose — the compound's obesity program was discontinued after mid-stage trials missed their endpoints. What exists instead is a community convention: research-peptide forums and vendors typically cite roughly 250–300 mcg once daily by subcutaneous injection. Those numbers describe what people say they do, not what any study validated.

The pattern most often repeated in community logs and vendor materials:

• Roughly 250–300 mcg once daily, injected subcutaneously.
• Often timed in the morning or fasted — a habit borrowed from lipolysis folklore, not from evidence.
• Frequently framed as multi-week cycles rather than continuous use.

These figures vary between sources and have no clinical anchor. Given that a company spent years failing to show weight loss with this molecule in supervised trials, community mcg numbers deserve extra skepticism rather than less: they specify with false precision the dose of an effect nobody has been able to measure in a human being.

The published research diverges from community practice in ways worth knowing:

• The foundational rat study gave AOD-9604 orally at 500 mcg/kg daily for 19 days — a weight-based lab dose, by mouth, not an injection (Hormone Research 2000).
• Mouse work used two weeks of intraperitoneal dosing — a route not used in humans at all (Endocrinology 2001).
• The human trials (phase IIa underway by 2002; Current Opinion in Investigational Drugs 2004) tested it as an obesity drug, but their dosing details and results were never published in a peer-reviewed journal.

In other words, the subcutaneous 250–300 mcg convention is not carried over from the science — it grew up independently of it.

AOD-9604 is sold as a lyophilized (freeze-dried) powder that must be dissolved in bacteriostatic water before use. Two mechanical details determine what a syringe actually delivers: the reconstitution volume (how much water is added sets the mg/mL concentration) and correctly reading insulin-syringe units as volume. The peptide calculator can handle the arithmetic; it cannot make an unvalidated number appropriate.

Dose-finding is a product of successful drug development: escalating studies, exposure measurements, and efficacy endpoints that define a therapeutic window. AOD-9604 never completed that process — development stopped, no label exists, and long-term human safety was never characterized. That also means basic pharmacokinetic questions have no public answers: how much of a subcutaneous dose reaches circulation, how fast it clears, and whether once-daily timing matches the molecule's actual behavior are all undetermined. Cycle lengths repeated in community logs (commonly "8–12 weeks") are equally unanchored — they migrated over from unrelated compounds rather than from anything measured with this one. Athletes have an added reason for caution: the compound is banned by WADA and detectable in urine (Drug Testing and Analysis 2015). For the fuller picture, see the main AOD-9604 page and its safety guide.